Alteogen Eyes ASEAN, OIC Biosimilar Markets Via Malaysian JV
Alteogen is taking a different strategy versus its bigger South Korean biosimilar rivals as it is aiming to enter the ASEAN and OIC biosimilar markets by establishing a joint venture with a state-owned Malaysian firm.
You may also be interested in...
South Korean biotech Alteogen is progressing the development of its Eylea biosimilar both at home and abroad, with the hope of becoming a global first mover with its version in wet AMD, backed by formulation and manufacturing patents.
As the year end approaches, Scrip wraps up what major events made headlines in the South Korean pharma/biotech sector in 2018.
Celgene reworks its collaboration with Abide, dropping its buyout option. Roivant gains Chinese rights to anti-infective lemafulin and adds a fifth candidate to Dermavant's pipeline, while pSivida acquires Icon and FDA-approved Dexycu for cataract surgery inflammation.